Note 3 — Revenue

The Company has two contracts with customers: a collaboration and license agreement with GSK (“the GSK Collaboration and License Agreement”) and a collaboration agreement with Astellas Pharma Inc. through its wholly-owned subsidiary, Universal Cells, Inc. (“Astellas”).

Revenue from contracts with customers in the three months ended March 31, 2020, which was included in the deferred income balance at January 1, 2020, comprises the following (in thousands):

​

​

The following table shows movements in deferred revenue for the three months ended March 31, 2020 (in thousands):

​

​

(1) Revenues from our collaboration agreements are generated by our U.K.-based subsidiary, which has a pounds sterling functional currency. As a result, the deferred revenue is subject to foreign currency translation adjustments when it is translated into U.S. dollars in the condensed consolidated financial statements.

​

The amounts invoiced in the period related to the $50.0 million upfront payment under the Astellas Collaboration Agreement. The revenue recognized in the period relates to work performed on products to the third target under the GSK Collaboration and License Agreement.

​

​

The Astellas Collaboration Agreement

On January 13, 2020, the Company entered into a collaboration agreement with Astellas Pharma Inc (“the Astellas Collaboration Agreement”). The Company received $50.0 million as a non-refundable upfront payment in January 2020 after entering into the agreement. Under the agreement the parties will agree on up to three targets and will co-develop T-cell therapies directed to those targets pursuant to an agreed research plan. For each target, Astellas will fund co-development up until completion of a Phase 1 trial for products directed to such target.

​

Upon successful completion of the Phase 1 trial for a product, Astellas and Adaptimmune will elect whether to progress with co-development and co-commercialization of such product, or to allow the other party to pursue the candidate independently. If the parties progress with co-development and co-commercialization of a product, then each party will grant the other party a co-exclusive license to co-develop and co-commercialize such product in the field of T-cell therapy. If a product is developed solely by one party, then the other party will grant to the continuing party an exclusive license to develop and commercialize such product in the field of T-cell therapy.

​

At March 31, 2020, the collaboration is in the early stages. In April, the parties agreed on the target for the first collaboration program, and discussions remain ongoing around the research plan for the program.

​

In addition, Astellas is also granted the right to develop, independently of Adaptimmune, allogeneic T-cell therapy candidates directed to two targets selected by Astellas. Astellas will have sole rights to develop and commercialize products resulting from these two targets.

​

Under the terms of the agreement, Adaptimmune could be entitled to receive up to $847.5 million in further payments, including:

​

​

In addition, Adaptimmune is entitled to receive research funding of up to $7.5 million per year on a per collaboration target basis and tiered royalties on net sales in the mid-single to mid-teen digits.

​

In consideration for rights under certain contributed Astellas technology for a product unilaterally developed by Adaptimmune, Astellas could be eligible to receive up to $552.5 million, including up to $147.5 million in milestone payments per product, and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune. In addition, Astellas will receive tiered royalties on net sales in the mid-single to mid-teen digits.

To the extent that Astellas and Adaptimmune co-develop and co-commercialize any product, the parties would share equally all worldwide costs and profits.

Either party can terminate the agreement in the event of material breach or insolvency of the other party. Astellas can terminate the Agreement for convenience in its entirety or partly in relation to any targets and products directed to such targets. Adaptimmune can terminate the Agreement for convenience in relation to any target it is unilaterally developing and to products directed to such target.

The Company has assessed the agreement under the provisions of ASC 606, Revenue from Contracts with Customers and ASC 808, Collaborative Arrangements. The Company determined that Astellas is a customer and has applied the provisions of ASC 606 to the contract and related performance obligations. The Company identified the following performance obligations under the agreement: (i) research services and rights granted under the co-exclusive for each of the three co-development targets and (ii) the rights granted for each of the two independent Astellas targets.

The aggregate transaction price at inception of the agreement is the $50.0 million upfront payment. Future development milestones are not considered probable as of March 31, 2020 and have not been included in the transaction price. Reimbursement of the research funding over the co-development period (up until completion of a Phase 1 trial for products directed to such target) is variable consideration and included in the transaction price to the extent that it is probable. The Company may also receive sales milestones upon the achievement of specified levels of annual net sales by Astellas under an independent Astellas program. These amounts have not been included within the transaction price as of March 31, 2020 because they are sales-based and will be recognized when the subsequent sales occur.

The aggregate transaction price is allocated to the performance obligations depending on the relative standalone selling price of the performance obligations. In determining the best estimate of the standalone selling price, the Company considered internal pricing objectives it used in negotiating the contract, together with internal data regarding the cost and margin of providing research services and adjusted-market data from comparable arrangements. The variable consideration will be allocated to the performance obligation to which it relates. At March 31, 2020, $7.0 million has been allocated to research services and rights granted under the co-exclusive license for each of the three co-development targets and $14.5 million has been allocated to the rights granted for each of the two independent Astellas targets.

The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. The Company expects to satisfy the performance obligations relating to the three co-development targets as development progresses and would recognize revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company considers that this depicts the progress of the project, where the significant inputs would be internal project resources and third-party costs. The determination of the percentage of completion will require the Company to estimate the costs-to-complete the project. The Company intends to make a detailed estimate of the costs-to-complete on an annual basis, which will be re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. The Company estimates that revenue allocated to the research services will be recognized over the period from the selection of the first target for development until the Phase 1 trial completes as development progresses.

The Company has determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they are right-to-use licenses.

The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreement as of March 31, 2020 was $47.3 million, which is recognized in deferred income.

​